Article Data

  • Views 289
  • Dowloads 123

Original Research

Open Access

Sustainable complete remission in recurrence yolk sac tumor patient treated with tandem high-dose chemotherapy and autologous stem cell

  • N. A. Abdullah1
  • P. N. Wang2
  • K. G. Huang3,*,
  • A. S. Adlan4
  • J. Casanova5

1Department of Obstetrics & Gynecology, Sultanah Bahiyah Hospital, Kedah (Malaysia)

2Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan (Taiwan)

3Department of Obstetrics and Gynecology Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Kwei-Shan, Tao-Yuan (Taiwan)

4Department of Obstetrics and Gynecology. University Malaya Medical Center, Faculty of Medicine, University of Malaya, Kuala Lumpur (Malaysia)

5Department of Obstetrics & Gynecology, Centro Hospitalar do Porto, Porto (Portugal)

DOI: 10.12892/ejgo340217 Vol.34,Issue 2,March 2013 pp.183-185

Published: 24 March 2013

*Corresponding Author(s): K. G. Huang E-mail: kghuang@ms57.hinet.net

Abstract

A 21-year-old lady diagnosed with Stage 3 ovarian yolk sac tumor (YST) underwent primary cytoreductive fertility sparing surgery, followed by conventional courses of platinum-based chemotherapy and etoposide. Recurrence at cul-da-sac was noted after a short period of remission and secondary debulking performed followed by four cycles of conventional chemotherapy. The patient’s disease progressed despite courses of treatments. A joint team management including a hematologist was commenced following the failure of conventional chemotherapies. Two cycles of high-dose chemotherapy (HDCT) with ifosfamide/cisplatin/etoposide (ICE) regimen, followed by autologous stem cell transplantation (ASCT) were given. With this salvage treatment, she remained in complete remission and disease-free for more than 30 months, while maintaining her reproductive function. These approaches appear to be effective as a salvage treatment in selected cases of patients with ovarian germ cell tumor, especially those who failed primary conventional chemotherapy.

Keywords

High-dose chemotherapy; Germ cell tumor; Autologous stem cell.

Cite and Share

N. A. Abdullah,P. N. Wang,K. G. Huang,A. S. Adlan,J. Casanova. Sustainable complete remission in recurrence yolk sac tumor patient treated with tandem high-dose chemotherapy and autologous stem cell. European Journal of Gynaecological Oncology. 2013. 34(2);183-185.

References

[1] Dallenbach P., Bonnefoi H., Pelte M.F., Vlastos G.: “Yolk sac tumours of the ovary: an update”. Eur. J. Surg. Oncol., 2006, 32, 1063.

[2] Pestasides D., Pectasides E., Kassanos D.: “Germ cell tumor of ovary”. Cancer Treat. Rev., 2008, 34, 427.

[3] El-Helw L., Coleman R.E.: “Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours’. Cancer Treat. Reviews, 2005, 31, 197.

[4] de La Motte Rouge T., Pautier P., Rey A., Duvillard P., Kerbrat P., Troalen F. et al.: “Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases”. Eur. J. Cancer, 2011, 47, 175. Epub 2010 Sep. 28.

[5] Li J., Yang W., Wu X.: “Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients”. Gynecol. Oncol., 2007, 105, 769.

[6] Mitchell P.L., Al-Nasiri N., A’Hern R., Fisher C., Horwich A., Pinkerton C.R. et al.: “Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases”. Cancer, 1999, 85, 2232.

[7] Connolly R.M., McCaffrey J.A.: “High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review”. Eur. Urol., 2009, 56, 57.

[8] Rick O., Siegert W., Beyer J.: “Chemotherapy in patients with metastatic or relapsed germ-cell tumours”. Cancer Treat. Rev., 2001, 27, 283.

[9] Kondagunta G.V., Bacik J., Sheinfeld J., Bajorin D., Bains M., Reich L. et al.: “Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors”. J. Clin. Oncol., 2007, 25, 85.

[10] Einhorn L.H., Williams S.D., Chamness A. et al.: “High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors”. NEJM, 2007, 357, 340.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top